Grey matter correlates of affective and somatic symptoms of premenstrual dysphoric disorder

Manon Dubol1, Johan Wikström2, Rupert Lanzenberger3, C. Neill Epperson4, Inger Sundström-Poromaa5,6 & Erika Comasco1,6*

Ovarian hormones fluctuations across the menstrual cycle are experienced by about 58% of women in their fertile age. Maladaptive brain sensitivity to these changes likely leads to the severe psychological, cognitive, and physical symptoms repeatedly experienced by women with Premenstrual Dysphoric Disorder (PMDD) during the late luteal phase of the menstrual cycle. However, the neuroanatomical correlates of these symptoms are unknown. The relationship between grey matter structure and PMDD symptom severity was delineated using structural magnetic resonance imaging during the late luteal phase of fifty-one women diagnosed with PMDD, combined with Voxel- and Surface-Based Morphometry, as well as subcortical volumetric analyses. A negative correlation was found between depression-related symptoms and grey matter volume of the bilateral amygdala. Moreover, the severity of affective and somatic PMDD symptoms correlated with cortical thickness, gyrification, sulcal depth, and complexity metrics, particularly in the prefrontal, cingulate, and parahippocampal gyri. The present findings provide the first evidence of grey matter morphological characteristics associated with PMDD symptomatology in brain regions expressing ovarian hormone receptors and of relevance to cognitive-affective functions, thus potentially having important implications for understanding how structural brain characteristics relate to PMDD symptomatology.

Specific to women's mental health, premenstrual dysphoric disorder (PMDD) is a mood disorder characterized by psychological (i.e. affective lability, irritability, depressed mood and anxiety), cognitive (i.e. difficulties concentrating), and physical (i.e. breast tenderness, feeling bloated, musculoskeletal pain) symptoms repeatedly occurring in the late luteal phase of the menstrual cycle1–3. It is estimated that 3–8% of women of reproductive age meet the criteria for PMDD as delineated by the Diagnostic and Statistical Manual of mental disorders (DSM)3. The severity of both psychological and physical PMDD symptoms interferes with the woman’s life (family, social, and work functioning), although the affective symptoms lead to greater impairment compared to physical symptoms4. As there is no evidence for increased or decreased ovarian hormone levels in women with PMDD, symptoms have been hypothesized to arise from maladaptive brain response to the ovarian hormone fluctuations5. Yet, the neural correlates of PMDD symptoms remain poorly understood. Recent neuroimaging findings suggest that the ovarian hormone fluctuations throughout the menstrual cycle influence brain structure in healthy women6,7. Thus, luteal phase-specific maladaptive structural responses to ovarian hormones fluctuations represent putative risk factors for PMDD. To date, brain surface correlates of PMDD symptomatology have not been investigated, and only one study investigated the grey matter volume (GMV) correlates of PMDD symptom severity, reporting negative results5. However, this study included a small sample of women with PMDD (n = 15) scanned across the entire luteal phase, likely covering asymptomatic time points, and important confounding factors such as total brain volume and body mass index (BMI) were not taken into account5. Furthermore, one study on healthy naturally cycling women suggests that regional GMV relates to subclinical premenstrual symptoms8. Hence, a comprehensive examination of the relationship between brain morphological measures and PMDD symptoms is missing. In line with recent evidence promoting the use of multimodal neuroimaging approaches in psychiatry

*email: erika.comasco@neuro.uu.se

1Department of Neuroscience, Science for Life Laboratory, Uppsala University, POB 593, 75124 Uppsala, Sweden. 2Department of Surgical Sciences, Neuroradiology, Uppsala University, Uppsala, Sweden. 3Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. 4Department of Psychiatry, Department of Family Medicine, University of Colorado School of Medicine-Anschutz Medical Campus, Aurora, USA. 5Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden. 6These authors contributed equally: Inger Sundström-Poromaa and Erika Comasco. 

https://doi.org/10.1038/s41598-022-07109-3
research\textsuperscript{10}, the combination of local voxel-wise measures of GMV with measures of cortical thickness and folding (i.e. cortical thickness, gyrification, sulcal depth and complexity) was here employed to yield a comprehensive analysis of grey matter structure in relation to PMDD symptomatology. The present study aimed at determining the relevance of GMV and surface morphology to PMDD symptomatology, by use of multiscale structural MRI (sMRI) analyses (i.e. voxel-based (VBM) and surface-based brain (SBM) morphometry and subcortical volumetric analyses) based on macroanatomical characteristics of cortical and subcortical grey matter. We report, for the first time, the brain structural signatures of PMDD symptoms assessed with sMRI by use of a whole-brain, automated neuroimaging analysis of VBM and SBM, complemented by cortical and subcortical region-of-interest (ROI) analyses, in a relatively large and finely characterized sample of women with PMDD.

**Results**

In this cross-sectional study that prospectively tracked PMDD symptoms on a daily basis, high-resolution T1 images were collected during the late luteal phase, and sMRI analyses (VBM, SBM, and subcortical volumetric analysis) were performed (Fig. 1). Fifty-one women with PMDD (22–46 years-old) were assessed (Table 1), all having a regular menstrual cycle and 41.2% being nulliparous. On average, they were mostly right-handed (94.1%), highly educated (74.5%) and employed (84.3%). Following two diagnostic menstrual cycles (DRSP scores presented in Table S1), PMDD symptoms of mild to moderate severity were reported in the late luteal phase of the scan month (Table 2).

**Whole-brain grey matter correlates of PMDD symptoms.** Associations between surface measures and Daily Record of Severity of Problems (DRSP) scores obtained from the whole-brain vertex-wise analyses are presented in Fig. 2 and Table S2 (a detailed description is provided as supplementary information). Among the
whole-brain results, correlation coefficients ranged from 0.48 to 0.58 (95% CI [0.23–0.73]), indicating moderate
correlations. The most significant findings (pFWE < 0.05 corrected for the number of voxels and tests) illustrate
positive correlations between sulcal depth measures in the left fusiform gyrus (FuG) and the scores of the total
DRSP, concentration and energy loss, as well as the score of irritability in the left posterior cingulate cortex
(PCC). At the whole-brain level, no significant associations between GMV and PMDD symptom severity were
detected (p > 0.05 FWE corrected).

ROI-based grey matter correlates of PMDD symptoms. Complementary to whole-brain explorative
analyses, ROI analyses were conducted to investigate the relationship between PMDD symptoms and a priori
defined brain structures, in line with previous neuroimaging findings on PMDD5. Relationships between DRSP
scores and measures of GMV extracted from cortical ROIs (prefrontal cortex (PFC), anterior cingulate cortex
(ACC), cerebellum vermis, parahippocampal gyrus (PHG), and insula) and from subcortical finer segmentation
of deep structures (amygdala, hippocampus) were investigated. Among the ROI results, correlation coefficients
ranged from 0.27 (95% CI [−0.01–0.50]) to 0.43 (95% CI [0.17–0.63]), indicating moderate correlations (Figs. 3
and 4). Among these findings, the strongest correlations primarily point to relationships between the severity of
various PMDD symptoms and amygdalar volume (Table S3), as well as surface measures of prefrontal, anterior
cingulate and parahippocampal regions (Table S4). A detailed description is provided as supplementary infor-
mation.

Discussion
We report on neuroanatomical correlates of symptom severity in women with PMDD, for the first time investi-
gated through a combined whole-brain and ROI multi-scale automated MR assessment ensuring high morpho-
logical accuracy. By taking advantage of the fact that PMDD symptoms may vary in intensity from cycle to cycle,
we found, in women already diagnosed with PMDD, that current variations in the severity of PMDD symptoms
were associated with surface measures, particularly in the prefrontal, cingulate and parahippocampal areas,
but also in insular, temporal, parietal, occipital and paracentral regions. Surface measures of the caudal ACC,
PHG, inferior-orbital PFC regions and FuG seemed particularly involved in PMDD symptomatology, as they
displayed correlations with the total DRSP score (Fig. S1). Additionally, PMDD symptom severity was associated

| Demographics and psychometrics | Mean ± SD or n (%) |
|--------------------------------|-------------------|
| Sample size (n)                | 51 (100%)         |
| Age (years)                    | 34.7 ± 6.0        |
| BMI                            | 23.7 ± 3.4        |
| Menarche (years)               | 13 ± 2            |
| Menstrual cycle length (days)  | 28 ± 2            |
| Nicotine users                 | 11 (21.6%)        |
| Smoking cigarettes             | 6 (54.5%)         |
| Dipping tobacco                | 6 (54.5%)         |
| Alcohol use (AUDIT score)      | 3.35 ± 2.28       |

| PMDD clinical characteristics  |                      |
|--------------------------------|-----------------------|
| Age at onset (years)           | 24 ± 7                |
| Illness duration (years)       | 11 ± 7                |
| Total DRSP score               | 70.6 ± 15.0           |
| Previous PMDD treatment        | 41 (80.4%)            |
| SSRI                           | 29 (70.7%)            |
| Hormonal treatment             | 21 (51.2%)            |
| Homeopathy                     | 9 (22.0%)             |
| Psychological support          | 4 (9.8%)              |
| Psychiatric history            | 22 (43.1%)            |
| Depressive disorder            | 17 (77.3%)            |
| Anxiety disorder               | 5 (22.7%)             |
| Depressive and anxiety disorders| 3 (13.6%)            |
| Anorexia                       | 2 (9.1%)              |
| Bulimia                        | 2 (9.1%)              |

| Hormonal concentrations        |                      |
|--------------------------------|-----------------------|
| Estradiol (pmol/L)             | 389.7 ± 239.3         |
| Progesterone (nmol/L)          | 21.2 ± 16.1           |

Table 1. Participants characteristics. AUDIT Alcohol use disorders test, BMI Body Mass Index, DRSP Daily
record of severity of problems, SD Standard deviation, SSRI Selective serotonin reuptake inhibitor.
to GMV of the amygdala. The present findings have implications for understanding how morphological brain characteristics relate to PMDD symptomatology.

The localization of the surface correlates of PMDD symptoms overlaps with brain regions whose fluctuations of GMV have been associated with the menstrual cycle in healthy women, such as the PHG, ACC, PFC and FuG7; all regions characterized by expression of ovarian hormone receptors11,12 and of relevance to cognitive-affective functions13. In addition, our findings relate to the Default Mode Network, where the PHG, ACC, PCC, precuneus, and medial PFC areas constitute anatomical and functional hubs14,15. In healthy women, menstrual cycle-related variations of functional connectivity were reported between regions of this network7, whose activity has been associated with depression16. Moreover, the functional connectivity of the PHG with the PCC has been associated with negative mood in patients with remitted depression17. Consistently, our results point towards associations between the affective core PMDD symptoms and the surface measures of the PHG (affective labil- ity, irritability and depression) and PCC (irritability). Furthermore, among the numerous correlations we found between PMDD symptom severity and surface parameters within frontal areas, most involved anterior cingulate and ventrolateral-orbital areas, although associations were also observed in ventromedial and dorsal areas, to a lesser extent. This is of particular interest, as the ACC and ventrolateral PFC are primarily involved in cognitive control, most commonly recruited during emotion regulation18. Corroborating findings from functional neuroimaging studies particularly highlight the implication of these regions in PMDD (e.g. blunted fronto-cingulate activation in PMDD patients while processing emotions19). To date, the sole SBM study comparing women with PMDD and healthy controls reports no differences in cortical thickness over the whole brain20. Thus, the present findings represent the first SBM analysis to provide evidence of associations between cortical morphology and the severity of PMDD symptoms, although causality could not be determined. Moreover, lateralized patterns of correlations between surface measures and symptom severity emerged from our findings, particularly in the ACC, PHG and orbitofrontal cortex (OFC). However, the asymmetry index of ROIs indicates minor differences

Table 2. Premenstrual symptom severity within the scan month in women with PMDD. The mean late luteal phase DRSP scores for individual items were obtained during the final five days of the menstrual cycle in the scan month. In addition, the mean late luteal phase total DRSP score, and DRSP subscales corresponding to the DSM-V domains were computed by summing the individual DRSP items. DSM Diagnostic and Statistical Manual of Mental Disorders, DRSP Daily Record of Severity of Problems, SD standard deviation.

| DSM-V domain | DSM-V domain abbreviation | DRSP item | Mean ± SD per DRSP item | Mean ± SD per DSM domain |
|--------------|---------------------------|-----------|-------------------------|-------------------------|
| Core symptoms | Marked affective lability | AFFECTIVE LABILITY | Had mood swings | 3.6 ± 1.4 | 6.9 ± 2.5 |
| | Marked irritability or anger | IRRITABILITY | Felt angry, irritable | 3.7 ± 1.4 | 6.7 ± 2.6 |
| | Markedly depressed mood | DEPRESSION | Felt depressed, sad, “down” or blue | 3.2 ± 1.2 | 9.3 ± 3.2 |
| | Felt hopeless | | 3.0 ± 1.1 |
| | Felt worthless or guilty | | 3.0 ± 1.1 |
| | Marked anxiety and tension | ANXIETY | Felt anxious, “keyed up” or ’on edge’ | 3.2 ± 1.3 |
| | Decreased interest in usual activities | ANHEDONIA | Had less interest in usual activities | 3.3 ± 1.2 |
| | Difficulty in concentration | CONCENTRATION | Had difficulty concentrating | 3.2 ± 1.3 |
| | Lethargy and marked lack of energy | ENERGY LOSS | Felt lethargic, tired, fatigued, or had a lack of energy | 3.6 ± 1.2 |
| | Marked change in appetite | APPETITE | Had increased appetite or overate | 2.5 ± 1.4 | 5.1 ± 2.6 |
| | Had specific food craving | | 2.6 ± 1.4 |
| | Hypersomnia or insomnia | SLEEP | Slept more, tool naps, found it hard to get up | 3.0 ± 1.1 | 5.7 ± 2.2 |
| | Had trouble getting to Sleep, staying asleep | | 2.7 ± 1.5 |
| | Feeling overwhelmed or out of control | OVERWHELMED | Felt overwhelmed, that I couldn’t cope | 3.1 ± 1.2 | 5.8 ± 2.2 |
| | Felt out of control | | 2.7 ± 1.2 |
| | Physical symptoms | PHYSICAL | Had breast tenderness | 2.4 ± 1.5 | 7.4 ± 3.4 |
| | Had breast swelling, felt bloated, or had gain weight | | 2.9 ± 1.5 |
| | Had joint or muscle pain | | 2.1 ± 1.2 |
| | — | Had headache | 2.1 ± 1.2 | — |
| | Total DRSP score | | | 62.3 ± 18.4 |
between the structural measures of the two hemispheres (Fig. S2), thus suggesting that PMDD symptoms arise from region- and hemisphere-specific function.

Complementary to surface results, the present volumetric findings show correlations between the PMDD symptom severity and subcortical GMV. Negative correlations were observed between GMV of the bilateral amygdala and the severity of affective core and secondary PMDD symptoms; which are all related to the depressive symptomatology. The amygdala is thought to play a role in depression, and is central to the hypothesized impairment of top-down inhibitory processes in PMDD. Indeed, the functional MRI literature points to concurrent hyperactivity of the amygdala and hypoactivity of dorsolateral prefrontal areas, both associated with PMDD symptom severity in the late luteal phase. Anatomical compensatory effects, or vice versa predisposition in terms of small regional volume, could be hypothesized to explain the hormonally-triggered exaggerated amygdalar functioning observed in PMDD. On the cellular level, in female rodents, ovarian hormones are involved in rapid fluctuations of dendritic density in the amygdala across the estrous cycle, as well as in depression- and anxiety-like behavior. Thus, decreasing hormones levels during the premenstrual phase could lead to decreasing GMV in this region and increased symptom severity in women with PMDD.

The observed correlations between psychological symptom severity and grey matter measures were located within the corticolimbic circuit, primarily in areas of relevance to interlinked cognitive and emotion processing. The findings involve limbic (amygdala), paralimbic (parahippocampus), and higher-order integrative cortical areas such as the PFC and ACC, known to be implicated in anxiety and depression. Thus, together with the albeit limited neuroimaging findings on PMDD and studies on mood disorders and healthy samples, the present

Figure 2. Whole-brain associations between surface measures and PMDD symptom severity. Results from partial correlation analyses ran to assess the relationship between brain surface measures and DRSP scores corresponding to PMDD symptoms as defined by the DSM-V domains. Unthresholded SPM T-maps are overlaid on an average central surface. Regions displaying significant (pFWE < 0.05) correlations with PMDD symptom severity are indicated by arrows. Positive and negative correlations between surface measures and DRSP scores are illustrated in red and blue, respectively. Findings not reaching statistical significance (pFWE < 0.05) are not represented. DRSP, Daily Record of Severity of Problems; Fusiform, Fusiform gyrus; IPL, inferior parietal lobule; ITG, inferior temporal gyrus; PCC, posterior cingulate cortex; Precentral, precentral gyrus; Postcentral, postcentral gyrus.
Figure 3. Correlation of GMV within ROI by PMDD symptom severity. (a) Correlation between DRSP scores corresponding to PMDD symptoms as defined by the DSM-V domains, and raw grey matter volume (GMV) within the cortical, and subcortical ROIs. The colors represent the correlation coefficient values. Positive and negative correlations are illustrated in red and blue respectively. $p < 0.05$ after correcting for TIV, age and BMI. Rectangles including left and right ROIs indicate significant correlations obtained for the bilateral average ROI. The correlation heatmap was generated using JMP10 (JMP, SAS Institute). (b) Scatterplots depicting the correlations between GMV of the left and right amygdala (raw values, unadjusted for TIV, age and BMI) and the total DRSP score, as well as the scores of the PMDD domains affective lability, depression, anhedonia, concentration, energy loss, sleep and overwhelmed ($-0.33 < r < -0.29$). Dotted lines indicate non-significant correlations. ACC anterior cingulate cortex, AMY amygdala, DRSP Daily Record of Severity of Problems, HC hippocampus, INS insula, L left, MFG middle frontal gyrus, OFC orbitofrontal cortex, R right, SFG superior frontal gyrus, VERMIS cerebellar vermis.
Figure 4. Correlation heatmaps of surface measures within ROI by PMDD symptom severity. Correlation between DRSP scores corresponding to PMDD symptoms as defined by the DSM-V domains, and surface parameters within the cortical ROIs: cortical thickness, gyrification index, sulcal depth, and cortical complexity. The colors represent the correlation coefficient values. Positive and negative correlations are illustrated in red and blue respectively. $\square$, $p < 0.05$ after correcting for TIV, age and BMI. Rectangles including left and right ROIs indicate significant correlations obtained for the bilateral average ROI. The correlation heatmaps were generated using JMP10 (JMP, SAS Institute).

ACC anterior cingulate cortex, CAUD caudal, DRSP Daily Record of Severity of Problems, L left, LAT lateral, MED medial, MFG middle frontal gyrus, OFC orbitofrontal cortex, PARS ORB pars orbitalis, PARS OPER pars opercularis, PARS TRI pars triangularis, PHG parahippocampal gyrus, R right, ROST rostral, SFG superior frontal gyrus.
somatization is involved in the severity of premenstrual symptoms in healthy women. Further, it has been proposed that the structure and function of the emotional brain plays a critical role in linking nociception and pain perception, in light of the interactions between anxiety, depression and pain. Remarkably, the regions where we found associations between surface measures and physical symptoms overlap with the ones for which we found associations with affective symptoms, namely the ACC, medial OFC, and inferior frontal gyrus (IFG) sub-regions. A symptoms-based discussion of the findings is presented as supplementary information.

In view of that PMDD symptom severity fluctuates as a main characteristic of the disorder, the present findings could suggest that the PMDD brain undergoes menstrual cycle-phase dependent structural changes in the neural network subserving corticoclimbic and related association areas, thus representing maladaptive neuroanatomical response to hormonal fluctuations. In line, the present neuroanatomical correlates of PMDD symptoms seem to differ from the anatomical signatures of PMDD, in comparison with healthy controls, which have been sparsely investigated by use of VBM and SBM analyses in four studies and yield conflicting results. While anatomical fluctuations occur in the brain of healthy naturally cycling women throughout the menstrual cycle, the late luteal phase remains virtually unstudied in healthy women. Correlates of emotion processing, cognition, brain metabolism and neurotransmission point to differential menstrual cycle-related neuroadapative changes in women with PMDD compared to healthy naturally cycling women, involving structures such as the PFC, insula, cerebellum, and amygdala, which overlap with the regions described as being influenced by the menstrual cycle in healthy women and the ones here indicated as correlates of PMDD symptom severity.

The present findings should be interpreted in light of the following methodological considerations. The current study displays a number of strengths compared to the neuroimaging literature on PMDD, such as the use of multi-scale, highly standardized, structural brain analyses and a rather large and well-characterized sample of women with PMDD. Furthermore, confirmation of menstrual cycle phase was ensured through both menstrual cycle mapping and hormonal assessment, and both age and BMI were considered as potential confounding factors influencing brain structure. Therefore, this study offers greater statistical power compared to previous work on PMDD. Thus, while Jeong et al. exclusively performed whole-brain voxel-wise analyses of GMV, we combined whole-brain investigations with a ROI approach providing increased sensitivity to the neuroimaging analyses by reducing the number of comparisons that need to be controlled for. In addition, we conducted subcortical segmentation of the hippocampus and amygdala, in order to circumvent the low contrast between tissues within subcortical structures in MR images. Of note, whole-brain analyses of GMV conducted in our sample of women with PMDD did not reveal any significant correlation with symptom severity, in accordance with Jeong et al. Furthermore, although VBM findings might be driven by variability in cortical thickness and/or folding, SBM provides complementary measures of cortical anatomy. Nevertheless, while the use of complementary assessments (i.e. VBM, SBM, subcortical segmentation) provides a multiscale overview of the structural variations that could relate to PMDD symptoms in the brain, some ROIs could not be accurately evaluated using a combination of these methods. Furthermore, although several of the ROI-based findings did not reach significance after correction for multiple testing, the observed correlation strength up to $r = 0.43$ indicates substantial associations between grey matter structure and PMDD symptoms. With a sample size of fifty-one women included in the analyses, our volumetric findings reached a statistical power up to 0.82 ($r = 0.43$), while the surface-based results reached a power up to 0.99 ($r = 0.58$). Nevertheless, in order to detect effects smaller than $r = 0.38$ at $\alpha = 0.05$ with a statistical power of at least 0.80, a larger sample of participants would be needed. In addition, as only women with PMDD were assessed in this study, we cannot exclude the possibility that the associations we found between grey matter structure and premenstrual symptoms also appear in healthy women experiencing premenstrual symptoms. Last, in future studies, it would be interesting to explore the relationship between PMDD symptoms severity and brain measures in the late luteal phase compared with the asymptomatic phase, as whether the present findings represent long lasting changes of the brain organization or late lutal-specific neuroplasticity is still to be determined.

The present findings point to multi-scale neuroanatomical correlates of symptom severity in PMDD patients, investigated through a combined whole-brain and ROI automated MR data analysis approach. Variations in the severity of PMDD symptoms were associated with the volume of the amygdala, as well as surface measures of prefrontal, cingulate, temporal, parietal, occipital and paracentral regions. The present findings move forward the field by addressing a gap, demonstrating that brain morphological characteristics are related with PMDD symptomatology and potentially have important implications for understanding differential brain function previously associated with PMDD.

Materials and methods
Participants. This study was carried out at the Departments of Obstetrics and Gynecology at Uppsala University Hospital, from 2016 to 2019. Sixty-two women with PMDD (22–46 years) with regular menstrual cycles (25–35 days), of Caucasian origin and Swedish-speaking were recruited by advertisement in local newspapers, boards, social media, and students' websites. Exclusion criteria were: steroid hormone treatment during the previous three months (including hormonal contraceptives), breast-feeding, pregnancy, presence of ongoing psychiatric disorders, treatment with psychotropic drugs during the previous three months, severe medical con-
PMDD diagnosis according to DSM-5 criteria was confirmed using daily prospective symptom ratings during two consecutive menstrual cycles with the Daily Report Severity of Problems (DRSP) scale (Table S1) using a smartphone application. Thus, the participants were required to present marked symptoms in the luteal phase, causing significant distress or interference with usual activities, to meet the PMDD diagnosis criteria. PMDD was defined as > 50% increase in at least five of eleven symptoms (among which at least one symptom was a core PMDD symptom) between the follicular (day 6 to 12) and luteal phase (day − 7 to − 1). Percent increase was calculated as [(mean luteal phase scores − mean follicular phase scores)/mean follicular phase scores] × 100. In addition, we required that diagnostic symptoms be at least mild (mean luteal phase score > 3.0; at least two days with scores ≥ 4) and disappeared during the follicular phase (mean follicular phase score < 2.0). Other psychiatric disorders were ruled out by the Mini-International Neuropsychiatric Interview35.

Primary measures of symptom severity included the mean late luteal phase total DRSP score obtained during the final 5 days of the scan month36. In addition, DRSP subscales were computed according to the DSM-5 categorization of PMDD core and secondary symptoms as described in37. DRSP sub-scales include core mood symptoms such as marked affective lability, marked irritability, marked depressed mood, anxiety, and secondary behavioral and somatic symptoms such as marked change in appetite, sleep, feeling overwhelmed, physical symptoms, anhedonia, problems concentrating and energy loss37. Monitoring of the menstrual cycle phase was confirmed by serum progesterone and estradiol concentrations. Due to technical issues (n = 3), brain tumor (n = 1), extreme BMI (n = 2), high AUDIT score (n = 1), missing DRSP data (n = 3) and poor grey matter segmentation output (n = 1), a total of eleven participants were excluded from the MR correlation analyses, which thus included fifty-one women.

Hormone analyses. Venous blood samples were collected from each participant at the beginning of every session to determine the levels of estradiol and progesterone. Serum steroid hormones concentrations were measured from 300 μL of sample material at the Core Facility of Metabolomics, University of Bergen, by liquid chromatography—tandem mass spectrometry. An Acquity UPLC system (Waters, Milford, MA, USA) was used to chromatographically separate the steroids on a C-18 column (50 × 2.1 mm, 1.7 mm particle size). The UPLC system was connected to a Waters Xevo TQ-S tandem mass spectrometer equipped with an electrospray ionization source, and the steroids were detected in negative (estradiol) or positive ion (progesterone) MRM mode. Analytical sensitivity and precision were determined as lower limit of detection and total coefficient of variation, respectively, for estradiol (3.6 pmol/L and 10.0%) and progesterone (0.21 nmol/L and 8.9%).

MR acquisition. All participants were asked to have their brain scanned at rest in the late luteal phase of the menstrual cycle. Acquisition of high-resolution Magnetic Resonance (MR) imaging data was conducted with a 3.0 Tesla whole-body scanner (Achieva dStream, Philips Medical Systems, Best, The Netherlands) equipped with a 32-channel head coil. Acquisition of anatomical 3D-T1-weighted whole-brain scans was carried out using a MPRAGE sequence with the following parameters: Repetition Time (TR) = 8.3 ms, Echo Time (TE) = 3.8 ms, 256 × 256 matrix size, flip angle = 8°, 220 slices, acquisition time: 3:50 min. Resulting images have a 0.94 × 0.94 × 1 mm³ voxel size with a dimension of 256 × 256 × 220.

Voxel-based morphometry. The MR preprocessing steps were run using the Statistical Parametric Mapping software (SPM12, Welcome Trust Centre for Neuroimaging, University College London, UK) implemented in MATLAB R2018a (MathWorks, Natick, MA, USA). First, all images were manually reoriented using the coordinate of the anterior commissure as origin (0, 0, 0), so that the orientation approximated MNI (Montreal Neurological Institute) space. Using the segment routine of SPM 12, the reoriented images were spatially normalized into the MNI space and corrected for intensity variations before being segmented into grey matter, white matter, cerebrospinal fluid, bone, soft tissue and background probability maps based on voxel intensities of MNI tissue probability maps38. Following segmentation, a modulation process was applied to the grey matter and white matter probability maps in order to compensate for the effects of spatial normalization on volumetric data. Finally, modulated grey matter probability maps were smoothed using an 8-mm full-width half-maximum (FWHM) Gaussian kernel, resulting in a 1.5 × 1.5 × 1.5 mm³ voxel size.

A quality assessment procedure including a visual inspection for apparent artefacts and an automated quality control using the CAT12 toolbox in SPM (http://dbm.neuro.uni-jena.de/vbm/check-sample-homogeneity) has been followed in order to detect image artefacts and anatomical outliers. Resulting from brain segmentation, the average total GMV was 0.73 ± 0.05 L, the average total white matter volume was 0.41 ± 0.04 L and the total cerebrospinal fluid was 0.33 ± 0.06 L. The mean Total Intracranial Volume (TIV) was 1.47 ± 0.09 L.

Subcortical segmentation. In order to circumvent the low contrast between tissues within subcortical structures in MR images32 affecting the accuracy of whole-brain segmentation pipelines, and obtain reliable estimations of subcortical regional volumes, we used the FSL-FIRST segmentation pipeline through the “run_first_all” script using default settings (FSL version 6.0.0). FSL-FIRST is based on a Bayesian probabilistic model relying on shape and intensity profiles to determine the location of subcortical structures, trained on 336 manually-labelled T1-weighted MR images. A full description of the pipeline is available in39. In brief, a two-stage affine registration to MNI space is applied, to the whole brain first and to subcortical regions secondarily. The segmentation process extracts each subcortical structure according to the model, based on shape and intensity. Last, a boundary correction is applied to the segmented images to classify the boundary voxels as belonging to
the structure or not and to correct for overlapping segmentations. FSLstats tool was used to estimate the mean volumes of the segmented left and right amygdala and hippocampus. The method has been shown to give accurate and robust results for the segmentation of subcortical structures, comparable to—or better than—other automated methods of subcortical segmentation 40, showing for example the least overestimation of hippocampal volumes 40.

Surface-based morphometry. For SBM preprocessing and analysis, we used the automated CAT12 preprocessing pipeline (http://dbm.neuro.uni-jena.de/cat). This pipeline includes a projection-based thickness estimation that allows the computation of cortical thickness and central surface in one step 41, along with partial volume correction and correction for sulcal blurring and sulcal asymmetries. A gyrification index was extracted based on absolute mean curvature 42. In addition, cortical complexity and sulcal depth measures were extracted. For inter-subject comparisons, the surface meshes were re-parameterized into a common coordinate system using spherical maps 43. Finally, all surface measures were resampled and smoothed with a Gaussian kernel, of 15 mm (FWHM) for cortical thickness and 20 mm (FWHM) for the other parameters. Following preprocessing, the automated CAT12 quality control module for surface data was used in order to exclude outliers.

Statistical analyses. Following preprocessing, fifty-one women with PMDD were included in the analyses. In order to account for the nuisance variance of regressors of non-interest, total brain volume (TIV), BMI and age were included as confounding covariates due to their influence on volumetric and surface measures 44–46. A flowchart illustrating MR preprocessing and morphological measures used in the statistical analyses is provided in Fig. 1.

VBM statistical analyses were carried out in SPM12. VBM exploratory analyses of grey matter probability maps consisted of voxel-wise correlation analyses conducted within an explicit mask of grey matter generated from the mean grey matter probability map of the whole sample with an absolute threshold set at 0.2. Additionally, we defined ROIs based on the results of the previous literature 47, including bilateral ACC, PFC, insula, and cerebellum vermis. PFC ROIs were divided into the OFC (gyrus rectus and orbital parts superior, middle and inferior frontal gyri), the inferior, middle and superior frontal gyri (IFG, MFG and SFG). The seven ROIs were defined according to the AAL atlas, using the Pickatlas toolbox in SPM12. Similar to voxel-wise analyses, we performed partial correlation analyses to explore the relationship between the clinical features of women with PMDD (DRSP scores) and the mean GMV extracted from both the cortical (ACC, insula, OFC, IFG, MFG, SFG and cerebellum vermis) and subcortical ROIs (amygdala and hippocampus).

SBM statistical analyses were carried out using the CAT12 toolbox in SPM12. We assessed the relationship between DRSP scores and brain surface parameters (including cortical thickness, gyrification index, cortical complexity and sulcal depth), using whole-brain vertex-wise correlation analyses. In addition, regional mean surface data were extracted using the automatic “Extract ROI-based surface values” and “Estimate mean values inside ROI” tools in CAT12, based on the FreeSurfer Desikan/Killiany atlas 47. Twelve bilateral ROIs were analyzed based on the results of the previous literature 48, including caudal ACC, rostral ACC, insula, PHG, and eight prefrontal regions (superior frontal, pars opercularis, pars orbitalis, pars triangularis, rostral middle frontal, caudal middle frontal, lateral orbitofrontal and medial orbitofrontal). Similar to VBM analyses, we performed partial correlation analyses to explore the relationship between ROI mean surface parameters and the clinical scores of women with PMDD.

Based on previous literature showing asymmetry in grey matter structure 49 and brain function related to emotion regulation 50, the ROI-based analyses were carried out for each hemisphere separately. In cases where a similar pattern of association between structural measures and symptom severity was observed for both hemispheres, we merged left and right ROIs to present the results of the average bilateral region. Statistical analyses conducted on ROI-extracted data were performed using the Statistical Package for the Social Sciences (SPSS) version 26, and the significance threshold was set at p < 0.05, uncorrected for multiple testing. According to the explorative approach of this original study, the ROI-based results are presented uncorrected for multiple testing, while indicating if significance was reached after correction [Bonferroni correction for the four affective core PMDD symptoms (pBonferroni < 0.0125), and the seven secondary symptoms (pBonferroni < 0.0071)]. Exploratory whole-brain analyses results were visualized at a significance threshold of p < 0.001 uncorrected for multiple testing, and were considered significant at p < 0.05 Family Wise Error (FWE) corrected. Trend-level results were defined as 0.05 < p < 0.1 for FWE-corrected statistics, and as 0.05 < p < 0.06 for ROI-based statistics uncorrected for multiple testing.

Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 2 August 2021; Accepted: 8 February 2022
Published online: 09 April 2022

References
1. A.P.A. Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5) (2013).
2. Epperson, C. N. et al. Premenstrual dysphoric disorder: Evidence for a new category for DSM-5. Am. J. Psychiatry 169, 465–475. https://doi.org/10.1176/appi.ajp.2012.11081302 (2012).
3. Halbreich, U., Borenstein, J., Pearlstein, T. & Kahn, L. S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28, 1–23. https://doi.org/10.1016/S0306-4530(03)00098-2 (2003).
43. Yotter, R. A., Thompson, P. M. & Gaser, C. Algorithms to improve the reparameterization of spherical mappings of brain surface meshes. J. Neuroimaging 21, e134-147. https://doi.org/10.1111/j.1552-6569.2010.00484.x (2011).
44. Barnes, J. et al. Head size, age and gender adjustment in MRI studies: A necessary nuisance? Neuroimage 53, 1244–1255. https://doi.org/10.1016/j.neuroimage.2010.06.025 (2010).
45. Zheng, F. et al. Age-related changes in cortical and subcortical structures of healthy adult brains: A surface-based morphometry study. J. Magn Reson Imaging 49, 152–163. https://doi.org/10.1002/jmri.26037 (2019).
46. Garcia-Garcia, I. et al. Neuroanatomical differences in obesity: Meta-analytic findings and their validation in an independent dataset. Int. J. Obes. 43, 943–951. https://doi.org/10.1038/s41366-018-0164-4 (2019).
47. Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968–980. https://doi.org/10.1016/j.neuroimage.2006.01.021 (2006).
48. Barnes, J. et al. Head size, age and gender adjustment in MRI studies: A necessary nuisance? Neuroimage 53, 1244–1255. https://doi.org/10.1016/j.neuroimage.2010.06.025 (2010).
49. Gainotti, G. A historical review of investigations on laterality of emotions in the human brain. J. Hist. Neurosci. 28, 23–41. https://doi.org/10.1080/0964704X.2018.1524683 (2019).

Acknowledgements
The authors would like to thank Siju John, Britt-Mari Bolinder, Hernani Vieira, Haro de Grauw, and Sara Nyback for their help with data collection, as well as Prof. Simon S. Hustad, Department of Clinical Science, University of Bergen, who performed the hormone analyses. This study was supported by the EU FP7-People-Cofund (INCA 600398), the Swedish Research Council (2015-00495; 2016-01439; 2020-01801), the Swedish Society of Medicine (SLS-573171, SLS-597211, SLS-789101) and the Swedish Brain Foundation (2020-0255). EC is a Marie Skłodowska Curie fellow and receives funds from SciLifeLab. The funding sources had no implication in designing the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Author contributions
Designing of the work (I.S.P., E.C., R.L., J.W., C.N.E.); Acquisition of data (I.S.P., E.C., J.W.); Analysis and interpretation of data (M.D.); Drafting the work (M.D., E.C.); All authors have approved the submitted version of the manuscript.

Funding
Open access funding provided by Uppsala University.

Competing interests
RL received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. CNE has served on the advisory board of Asarina Pharma and Sage Therapeutics and has received research funding from and served as a consultant and advisory board member for Sage Therapeutics. ISP has served occasionally on advisory boards or acted as invited speaker at scientific meetings for Asarina Pharma, Bayer Health Care, Gedeon Richter, Peptonics, Shire/Takeda, Sandoz, and Lundbeck A/S. All other authors declare that they have no conflict of interest.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-07109-3.

Correspondence and requests for materials should be addressed to E.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022